Clinical Trial

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Study acronym: LuPARP
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase 1 dose-escalation and dose-expansion study is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) in patients with metastatic castration resistant prostate cancer (mCRPC).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-03-12; most recent amendment 2025-05-09.
Status change: Recruiting → Active, Not Recruiting 2025-05-09
Status change: Not Yet Recruiting → Recruiting 2019-07-17
Trial Details
NCT Number NCT03874884
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Conditions Metastatic Castration Resistant Prostate Cancer (mCRPC)
Enrollment 70 participants
Start Date 2019-07-09
Primary Completion 2025-05 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-05-14